1.	Phase III Randomized Study of Intermittent Versus Continuous Combined Androgen-Deprivation Therapy Comprising Bicalutamide and Goserelin in Patients With Metastatic Stage IV Prostate Cancer Responsive to Such Therapy Phase: Phase III Type: Treatment Status: Active Age: Adult Sponsor: NCI Protocol IDs: SWOG-9346, SWOG-9346, CAN-NCIC-PR8, CALGB-9594, ECOG-S9346, EORTC-30985, CAN-NCIC-JPR8, INT-0162, NCT00002651, PR8
2.	Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy Phase: Phase III Type: Treatment Status: Active Age: 20 to 79 Sponsor: Other Protocol IDs: JCOG0401, C000000026, NCT00138008
3.	Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial Phase: Phase III Type: Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: 05-8-4, NCT00243646
4.	Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: CDR0000571528, MRC-RADICALS-PR10, ISRCTN40814031, EUDRACT-2006-000205-34, EU-20767, PR13, NCT00541047
5.	Phase III Randomized Study of Prostate Bed Radiotherapy (PBRT) Alone Versus Short Term Androgen Deprivation Comprising Antiandrogen and Luteinizing Hormone-Releasing Hormone Agonist Therapy and Pelvic Lymph Node Radiotherapy With Versus Without PBRT in Patients With a Rising Prostate-Specific Antigen After Radical Prostatectomy for Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0534, RTOG 0534, NCT00567580
6.	Phase III Randomized Study of Radiotherapy With or Without Short-Term Androgen-Deprivation Therapy in Patients With Intermediate-Risk Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0815, RTOG 0815, NCT00936390
7.	Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A-93-52030-738, NCT01313273
8.	Phase III Randomized Study of Androgen-Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Patients With Unfavorable Intermediate- or Favorable High-Risk Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0924, RTOG-0924, NCT01368588
9.	Phase III Study of Dose-Escalated Radiation Therapy and Standard Androgen-Deprivation Therapy (ADT) With a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus Dose-Escalated Radiation Therapy and Enhanced ADT With a LHRH Agonist and Steroid 17alpha-monooxygenase TAK-700 in Patients With High-Risk Prostate Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-1115, RTOG-1115, NCT01546987
10.	Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NYU 08-479, NCT00878436
11.	Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer. Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OZM-011, NCT00757692
12.	Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-190, NCT00776594
13.	Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000628778, Novartis, UCDCC-215, 200816326-1, NOVARTIS-UCDCC-215, NCT00814788
14.	Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DUT112661, Health Canada-112661, NCT00866554
15.	Phase II Randomized Study of Combined Androgen Deprivation Comprising Bicalutamide and Goserelin or Leuprolide Acetate With Versus Without Cixutumumab in Patients With Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0925, S0925, NCT01120236
16.	Phase II Randomized Study of Bicalutamide With Versus Without Akt Inhibitor MK2206 in Patients With Prostate Cancer and Rising PSA at High-Risk of Progression After Primary Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E2809, E2809, NCT01251861
17.	A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9785-CL-0222, 2010-021868-15, NCT01288911
18.	Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16684, NCT01531205
19.	TAK-700 in Castration Resistant Prostate Cancer Phase: Phase II Type: Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: EORTC-1211, 2012-002122-67, NCT01658527
20.	Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MDV3100-09, NCT01664923
21.	Degarelix Neo-Adjuvant Radical Prostatectomy Trial Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: DEG_PRE-OP_001, Degarelix Pre-Op, NCT01674270
22.	Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer Phase: Phase I Type: Treatment Status: Active Age: Under 80 Sponsor: Other Protocol IDs: CDR0000639358, CLCC-RHOMUS, CRAD001 C2486, INCA-RECF0921, EUDRACT-2007-003620-38, RHOMUS, NCT00943956
23.	Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11D.243, 2011-32, NCT01420250
24.	Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: UMCC 2011.008, HUM00047650, NCT01642732
25.	Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000639281, ICORG-06-15, EU-20921, NCT00955435